Puma Biotechnology reports developments for a biopharmaceutical company built around oncology drug commercialization and development. Company news commonly centers on NERLYNX®, its oral neratinib product for HER2-positive breast cancer, including net product revenue, cost of sales, royalty revenue and financial outlook tied to demand for the therapy.
Updates also cover alisertib, a selective, orally administered aurora kinase A inhibitor licensed for development and commercialization. Puma describes the ALISCA™-Lung1 Phase II trial in extensive-stage small cell lung cancer and the ALISCA™-Breast1 Phase II trial in HER2-negative, HR-positive metastatic breast cancer, along with employee inducement equity awards under Nasdaq Listing Rule 5635(c)(4) and investor conference activity.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Puma Biotechnology, Inc. (NASDAQ: PBYI) is set to hold a conference call on May 4, 2023, at 1:30 p.m. PDT to discuss its first quarter 2023 financial results. The call can be accessed domestically at 1-877-709-8150 and internationally at 1-201-689-8354. A live webcast will also be available on Puma's website, along with a replay accessible for 90 days post-call.
As a biopharmaceutical company, Puma is focused on developing innovative cancer care therapies. Its product NERLYNX® (neratinib) has been approved for treating certain breast cancer cases. In addition, Puma has licensed the development rights for alisertib, an anti-cancer drug aimed at small cell lung cancer and breast cancer.
Puma Biotechnology, Inc. (NASDAQ: PBYI) announced on April 8, 2023, the grant of inducement restricted stock unit awards covering 22,000 shares to four new non-executive employees. These awards are part of Puma's 2017 Employment Inducement Incentive Award Plan and are intended to incentivize new hires. The units will vest over a three-year period, with a third vesting after the first anniversary and the remainder vesting in six-month increments thereafter, based on continued employment. Puma focuses on innovative cancer treatments, notably through its drug NERLYNX® (neratinib), which is approved for specific breast cancer treatments. Additionally, Puma holds an exclusive license for the anti-cancer drug alisertib, targeting lung and breast cancers.